Moderate Evidence
Research Overview
MariTide Research for Type 2 Diabetes
An evidence-based overview of research examining MariTide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 trials in T2D patients with obesity showed approximately 17% weight loss at 52 weeks along with significant HbA1c improvements. The MARITIME-2 Phase 3 trial is evaluating efficacy in this population over 72 weeks.
Other Peptides Studied for Type 2 Diabetes
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. MariTide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.